Skip to main content

Immunotherapy for refractory pulmonary infection after adult cardiac surgery: immune dysregulation syndrome.

Publication ,  Journal Article
Rankin, JS; Glower, DD; Teichmann, TL; Muhlbaier, LH; Stratton, CW
Published in: J Heart Valve Dis
November 2005

BACKGROUND AND AIM OF THE STUDY: Pulmonary dysfunction/multiorgan failure (PD/MF), usually due to refractory pulmonary infection, is an important cause of mortality and morbidity after cardiac operations. Moreover, the incidence of PD/MF may be increasing due to the emergence of antibiotic-resistant pathogens. METHODS: Fifteen consecutive patients (median age 69 years) who were developing antibiotic-refractory PD/MF were administered 24 g per day intravenous immunoglobulin (IV-IgG; Carimune) for five days. Ten patients had undergone complex valve surgery, and five coronary bypass. Preoperatively, 93% of patients had significant comorbidity, 73% presented acutely, 53% were hypoalbuminemic and 47% had antecedent acute pulmonary derangement. Clinical variables were assessed by retrospective chart review for three days prior to (-3) the start of IV-IgG (day 0) and for five days afterwards (+5). A postoperative morbidity index (PMI) was generated as a weighted sum of: worsening lung infiltrates (I); leukocytosis (L); pulmonary dysfunction (P); ventilator requirement (V); septic shock (S); renal (R), gastrointestinal (G), or hepatic (H) dysfunction; thrombocytopenia (T); and delirium (D). RESULTS: At day 0, all patients were refractory to major antibiotics, with morbidities of: 1-100%, L-93%, P-93%, V-60%, S-27%, R-67%, G-40%, H-13%, T-27%, and D-20%. Using regression analysis, IV-IgG administration was associated with a statistically significant fall in white blood count and improvement in PMI (p <0.006). Fourteen patients (93%) recovered uneventfully, and one patient (7%) died from progressive sepsis. No complications of IV-IgG therapy occurred. CONCLUSION: Given the high predicted mortality of PD/MF patients, these data suggest that IV-IgG is a safe and efficacious adjunct to antibiotics in this setting. Further studies, including a randomized trial and investigation of immunomodulatory mechanisms, seem indicated.

Duke Scholars

Published In

J Heart Valve Dis

ISSN

0966-8519

Publication Date

November 2005

Volume

14

Issue

6

Start / End Page

783 / 791

Location

England

Related Subject Headings

  • Respiratory Tract Infections
  • Respiratory System
  • Postoperative Complications
  • Middle Aged
  • Male
  • Lung Diseases
  • Leukocyte Count
  • Immunotherapy
  • Immunologic Factors
  • Immunoglobulins, Intravenous
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Rankin, J. S., Glower, D. D., Teichmann, T. L., Muhlbaier, L. H., & Stratton, C. W. (2005). Immunotherapy for refractory pulmonary infection after adult cardiac surgery: immune dysregulation syndrome. J Heart Valve Dis, 14(6), 783–791.
Rankin, J Scott, Donald D. Glower, Tracey L. Teichmann, Lawrence H. Muhlbaier, and Charles W. Stratton. “Immunotherapy for refractory pulmonary infection after adult cardiac surgery: immune dysregulation syndrome.J Heart Valve Dis 14, no. 6 (November 2005): 783–91.
Rankin JS, Glower DD, Teichmann TL, Muhlbaier LH, Stratton CW. Immunotherapy for refractory pulmonary infection after adult cardiac surgery: immune dysregulation syndrome. J Heart Valve Dis. 2005 Nov;14(6):783–91.
Rankin, J. Scott, et al. “Immunotherapy for refractory pulmonary infection after adult cardiac surgery: immune dysregulation syndrome.J Heart Valve Dis, vol. 14, no. 6, Nov. 2005, pp. 783–91.
Rankin JS, Glower DD, Teichmann TL, Muhlbaier LH, Stratton CW. Immunotherapy for refractory pulmonary infection after adult cardiac surgery: immune dysregulation syndrome. J Heart Valve Dis. 2005 Nov;14(6):783–791.

Published In

J Heart Valve Dis

ISSN

0966-8519

Publication Date

November 2005

Volume

14

Issue

6

Start / End Page

783 / 791

Location

England

Related Subject Headings

  • Respiratory Tract Infections
  • Respiratory System
  • Postoperative Complications
  • Middle Aged
  • Male
  • Lung Diseases
  • Leukocyte Count
  • Immunotherapy
  • Immunologic Factors
  • Immunoglobulins, Intravenous